Product Information
NEOMYC-POLYM-GRAMICID EYE DROP is a generic product labeled by Bausch & Lomb Incorporated, priced at $4.5856 per ML under NDC 24208079062. Its NADAC has been published 632 times since Nov 28, 2013.
FDA first approved this application on Jan 31, 1996. Its Orange Book therapeutic-equivalence code is AT.
Strength
.025; 1.75; 10000 mg/mL; mg/mL; [USP'U]/mL
Manufacturer
Bausch & Lomb IncorporatedNDC
24208079062
Classification
Generic
Dosage Form
SOLUTION/ DROPS
Route
OPHTHALMIC
Effective Date
9/23/2026
Active Ingredients
GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATEApproval Type
Generic (ANDA)
FDA Application
ANDA064047FDA Approved
1/31/1996
TE Code
AT
On Market Since
1/31/1996
Pharmacological Classes
Price Statistics
The NADAC for NEOMYC-POLYM-GRAMICID EYE DROP has been published 632 times since Nov 28, 2013, and over the history we have for it it has risen 6.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $4.5856 per ML |
|---|---|
| All-time high | $5.0002 (Aug 16, 2017) |
| All-time low | $3.7458 (Jul 17, 2024) |
| 52-week high | $4.7341 |
| 52-week low | $4.2473 |
| Median price | $4.5678 |
| Average price | $4.5166 |
| Largest weekly change | -15.6% (Apr 18, 2018) |
| Weeks tracked | 632 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the neomycin sulfate, polymyxin b sulfate and gramicidin market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Bausch & Lomb Incorporated manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
neomycin sulfate, polymyxin b sulfate and gramicidin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aminoglycoside Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of NEOMYC-POLYM-GRAMICID EYE DROP?
The current National Average Drug Acquisition Cost (NADAC) for NEOMYC-POLYM-GRAMICID EYE DROP, manufactured by Bausch & Lomb Incorporated, is $4.5856 per ML (NDC 24208079062), effective Sep 30, 2026.
How has the price of NEOMYC-POLYM-GRAMICID EYE DROP changed over time?
Over the history we have for it, the NADAC for NEOMYC-POLYM-GRAMICID EYE DROP has risen 6.0%. It has been tracked across 632 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for NEOMYC-POLYM-GRAMICID EYE DROP?
Since Nov 28, 2013, the NADAC for NEOMYC-POLYM-GRAMICID EYE DROP has ranged from a low of $3.7458 (Jul 17, 2024) to a high of $5.0002 (Aug 16, 2017), with a median of $4.5678 per ML.
Are there cheaper alternatives to NEOMYC-POLYM-GRAMICID EYE DROP?
No other NADAC-published product currently shares the active ingredient and strength of NEOMYC-POLYM-GRAMICID EYE DROP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures NEOMYC-POLYM-GRAMICID EYE DROP?
NEOMYC-POLYM-GRAMICID EYE DROP (NDC 24208079062) is labeled by Bausch & Lomb Incorporated, and CMS classifies it as a generic product.